Abstract
From the medical, pharmaceutical, and social perspectives, 2021 has been a year dominated by the COVID-19 pandemic. However, despite this global health crisis, the pharmaceutical industry has continued its endeavors, and 2021 could be considered an excellent year in terms of the drugs accepted by the US Food and Drug Administration (FDA). Thus, during this year, the FDA has approved 50 novel drugs, of which 36 are new chemical entities and 14 biologics. It has also authorized 10 TIDES (8 peptides, 2 oligonucleotides), in addition to 2 antibody-drug conjugates (ADCs) whose structures contain peptides. Thus, TIDES have accounted for about 24% of the approvals in the various drug categories. Importantly, this percentage has surpassed the figure in 2020 (10%), thus reflecting the remarkable success of TIDES. In this review, the approved TIDE-based drugs are analyzed on the basis of their chemical structure, medical target, mode of action, administration route, and adverse effects.
Highlights
Inclisiran is the third drug in which enhanced stabilization chemistry (ESC) within the double strands is conjugated to GalNAc ligand, as previously used in Lumasiran [5] and Givosiran [6]
F18 injection indicated for positron tomography prostate-specific membrane antigenis(PSMA)-positive lesions in emission men with prostate cancer(PET) o prostate-specific membrane (PSMA)-positive lesions in men with prostate with suspected metastasis whoantigen are candidates for initial definitive therapy, or with sus- cancer with suspected metastasis who serum are candidates for initial definitive therapy, pected recurrence based on elevated prostate-specific antigen (PSA) levels
A total of eight peptides, two oligonucleotides, and two antibody-drug conjugates (ADCs) containing peptides out of fifty drugs have been approved by the Food and Drug Administration (FDA) during 2021
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. At the end of 2020, public health analysts predicted that massive vaccination campaigns would bring about a new kind of “normal” to daily life. The variants driving the pandemic have not impeded the pharmaceutical industry from having an excellent year in terms of new approvals by the US Food and Drug Administration (FDA). In this regard, in 2021 (almost referred to as “this year”), the FDA has approved 50 drugs, bringing the total number of authorizations to 278 over the last six years [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
